Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells

Inflammation Research

Volumn 54, Issue 5, 2005, Pages 194-203

  Suuronen, T ^a   Nuutinen, T ^a   Huuskonen, J ^a   Ojala, J ^a   Thornell, A ^b   Salminen, A ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Estrogen; HDAC; Innate immunity; Lipopolysaccharide; Neuroinflammation

Indexed keywords

9 METHYLADENINE; CYTOKINE; ESTRADIOL; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; OLIGONUCLEOTIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRICHOSTATIN A;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; INFLAMMATION; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; NORTHERN BLOTTING; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; BLOTTING, NORTHERN; CELL PROLIFERATION; CELLS, CULTURED; CPG ISLANDS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; HIPPOCAMPUS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NITRIC OXIDE; OLIGONUCLEOTIDES; PROTEIN BINDING; RALOXIFENE; RATS; RATS, WISTAR; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS;

EID: 21144444356     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-005-1343-z     Document Type: Article

References (49)

1. Wyss-Coray T, Mucke L, Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002; 35: 419-32.
2. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003; 24: 321-31.
3. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22: 799-809.
4. Brinton RD. Cellular and molecular mechanisms of estrogen regulation of memory functions and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 2001; 8: 121-33.
5. Kesslak JP. Can estrogen play a significant role in the prevention of Alzheimer's disease? J Neural Transm Suppl 2002; 62: 227-39.
6. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD. Estradiol down-regulates LPS-induced cytokine production and NF-ÍB activation in murine macrophages. Am J Reprod Immunol 1997; 38: 46-54.
7. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001; 21: 1809-18.
8. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002; 67: 1379-85.
9. Azcoitia I, Doncarlos LL, Garcia-Segura LM. Estrogen and brain vulnerability. Neurotox Res 2002; 4: 235-45.
10. Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2004; 81: 231-41.
11. Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR. CNS: sex steroids and SERMs. Ann NY Acad Sci 2003; 997: 378-88.
12. Saunders-Pullman R. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine 2003; 21: 81-7.
13. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 2003; 46: 883-908.
14. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29.
15. Zhou W, Koldzic-Zivanovic N, Clarke CH, De Beun R, Wasserman K, Bury PS et al. Selective estrogen receptor modulator effects in the rat brain. Neuroendocrinology 2002; 75: 24-33.
16. Morris C, Wakeling A. Fulvestrant ('faslodex') - a new treatment option for patients progressing on prior endocrine therapy. Endocrine Cancer 2002; 9: 267-76.
17. Bruce-Keller AJ, Keeling JL, Keller JN, Huang FF, Camondola S, Mattson MP. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 2000; 141: 3646-56.
18. Falkenstein E, Tillmann H-C, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52: 513-55.
19. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades, part I: membrane-associated signaling complexes. Trends Endocrinol Metabol 2002; 13: 349-54.
20. Coleman MK, Smith CL. Intracellular signaling pathways: nongenomic actions of estrogen and ligand-independent activation of estrogen receptors. Front Biosci 2001; 6: D1379-91.
21. Corradin SB, Mauel J, Donini SD, Quattrocchi E, Ricciardi-Castagnoli P. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 1993; 7: 255-62.
22. Kerokoski P, Soininen H, Pirttilä T. Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality. Neurochem Int 2001; 38: 127-34.
23. Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003; 87: 407-16.
24. Helenius M, Kyrylenko S, Vehvilainen P, Salminen A. Characterization of aging-associated up-regulation of constitutive nuclear factor-κB binding activity. Antioxid Redox Signal 2001; 3: 147-56.
25. Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol 2004; 141: 874-80.
26. Kirschning CJ, Bauer S. Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 2001; 291: 251-60.
27. Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy 2002; 1: 181-91.
28. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with toll-like receptor 9. Semin Immunol 2004; 16: 17-22.
29. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (tlr9). FASEB J 2004; 18: 412-4.
30. Chen ZJ, Vetter M, Chang GD, Liu S, Ding Y, Chang CH. Nongenomic effects of tamoxifen on the activation of membrane bound guanylate cyclase GC-A. J Pharm Pharmacol 2003; 55: 1539-45.
31. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003; 59: 883-92.
32. Stork S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004; 15: 66-72.
33. Thomas T, Bryant M, Clark L, Garces A, Rhodin J. Estrogen and raloxifene activities on amyloid-β-induced inflammatory reaction. Microvasc Res 2001; 61: 28-39.
34. Lei DL, Long JM, Hengemihle J, O'Neill J, Manaye KF, Ingram DK et al. Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice. Neuroscience 2003; 121: 659-66.
35. Yang SH, Liu R, Wu SS, Simpkins JW. The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann NY Acad Sci USA 2003; 1007: 101-7.
36. Henderson VW. Hormone therapy and Alzheimer's disease: benefit or harm? Expert Opin Pharmacother 2004; 5: 389-406.
37. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD et al. Tamoxifen and cardiac risk factors in healthy woman, suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001; 21: 255-61.
38. Misiewicz B, Griebler C, Gomez M, Raybourne R, Zelazowska E, Sternberg EM. The estrogen antagonist tamoxifen inhibits carrageenan induced inflammation in lew/n female rats. Life Sci 1996; 58: PL281-6.
39. Taranta A, Brama M, Teti A, de Luca V, Scandurra R, Spera G et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002; 30: 368-76.
40. Drew PD, Chavis JA. Female sex steroids: effects upon microglial cell activation. J Neuroimmunol 2000; 111: 77-85.
41. Baker AE, Brautigam VM, Watters JJ. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor β. Endocrinology 2004; 145: 5021-32.
42. Mandlekar S, Kong A-NT. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6: 469-77.
43. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004; 91: 491-503.
44. Mercier I, Mader S, Calderone A. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 2003; 59: 883-92.
45. Perry RR, Kang Y, Greaves BR. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 1995; 72: 1441-6.
46. Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or sensitivity to cisplatin. Endocrinology 2004; 145: 1302-13.
47. Le Y, Iribarren P, Gong W, Cui Y, Zhang X, Wang JM. TGF-beta1 disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. J Immunol 2004; 173: 962-8.
48. Gabai VL, Yaglom JA, Volloch V, Meriin AB, Force T, Koutroumanis M et al. Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death. Mol Cell Biol 2000; 20: 6826-36.
49. Hamilton KL, Mbai FN, Gupta S, Knowlton AA. Estrogen, heat shock proteins, and NF κB in human vascular endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 1628-33.